Novel Method for Inducing Tissue Repair

Inventor(s)

Meenhard Herlyn and Mark Nesbit

Tech ID
HM96001
Background

The healing of open wounds or replacement of lost tissue following injury, reconstructive surgery, transplantation or loss of blood supply requires the formation of new blood vessels as well as the growth of organized tissue. At present there are no reproducible procedures to speed up tissue growth, which requires formation of extracellular matrix and collagens by activated fibroblasts, and to induce new blood vessel formation. Recombinant tissue growth factors have been utilized for this purpose with limited success due to their short half-life in vivo, limited penetration into deeper tissue regions, and difficulty in application directly to naturally healing tissue.

 

Wistar scientists have constructed replication-defective recombinant adenoviruses which express platelet-derived growth factor B (PDGF-B), vascular endothelial growth factor (VEGF) as well as other growth factors. Clinical trials of these vectors to enhance wound healing in diabetic ulcers have been planned; additional applications of the technology, including the use of the vectors in tissue engineering are in development. 

Key Words
dermatologic, Therapeutic, tissue engineering, wound healing
Applications and Advantages

Following simple injection, these viruses can induce the formation of either blood vessels (VEGF) or new stromal tissue (PDGF-B). The stimulation in vivo is self-limiting because the viruses are replication defective. These viruses may be useful for inducing wound healing and tissue repair in a variety of situations, including wound healing, reconstructive surgery and transplantation.

Intellectual Property Status

U.S. Patent No. 6,486,133.

Licensing Opportunity

Wistar is seeking an exclusive licensee and/or sponsored research to support the development of this technology.